Cavendish Financial PLC AGM Trading Statement (0410O)
29 Septiembre 2023 - 1:00AM
UK Regulatory
TIDMCAV
RNS Number : 0410O
Cavendish Financial PLC
29 September 2023
29 September 2023
For immediate Release
Cavendish Financial plc ("Cavendish" or the "Group")
AGM Trading Statement
Cavendish Financial plc announces the following update ahead of
its Annual General Meeting to be held today at 10.00 am:
On 8 September, finnCap Group plc and Cenkos Securities plc
completed their merger to create Cavendish Financial plc, a
full-service investment bank for ambitious growth companies.
The combined operation consists of just under 200 people
operating from its headquarters in One Bartholomew Close, London
and its Scottish office in Edinburgh. With 220 quoted clients, the
Group has the largest retained client base amongst UK small and
midcap investment banks, making it the go-to financial advisory
firm for growth and investment companies. In addition to equity
capital markets, Cavendish has expertise in M&A, debt advisory
and private growth capital. The Group also has a strong global
reach through its membership of Oaklins, an international advisory
network.
Since the merger, the Group has relocated all of the London
based Cenkos team to its London headquarters, launched the new
operating brand Cavendish, centralised trading onto a single
platform and made substantial progress with its IT integration. The
integration of the operations team, a key part of delivering the
synergies is also nearing completion. The Group will provide a
further update on synergy realisation within its inaugural interim
results expected to be announced in December.
Trading across the City has been quiet during the Summer, but
since merger completion the Group has already announced a number of
significant transactions which will close in the coming months
including acting as sole adviser to Round Hill Royalty Fund Limited
on its offer from Concord Cadence Limited, fundraisings for Haydale
Graphene PLC and Shield Therapeutics plc and obtaining key
regulatory clearances for the equity financing of Allergy
Therapeutics by ZQ Capital and Southern Fox.
Contacts:
Cavendish Financial plc Tel: +44 (0)20 7220 0500
John Farrugia, co-CEO
Julian Morse, co-CEO
Grant Thorton UK LLP (Nominated Adviser to Cavendish) Tel: +44
(0)20 7383 5100
Philip Secrett/Samantha Harrison/Samuel Littler
Hudson Sandler (PR adviser to Cavendish)
Dan de Belder
Tel: +44 (0) 7977 927142
Rebekah Chapman
Tel: +44 (0) 7702 596674
About Cavendish
Cavendish is a UK champion for ambitious growth and investment
companies. The Group is trusted by public and private companies,
operating across industry sectors, to deliver expert services in
equity capital markets, M&A, debt advisory and growth
capital.
Cavendish has offices in the City of London and Edinburgh and
has a global reach through its membership of Oaklins. Cavendish
Financial plc is quoted on AIM.
For more information on Cavendish, please visit
www.cavendish.com
END
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMUWROROUUKUAR
(END) Dow Jones Newswires
September 29, 2023 02:00 ET (06:00 GMT)
Finncap (LSE:FCAP)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Finncap (LSE:FCAP)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025